Moderna’s chairman, Noubar Afeyan

CAMBRIDGE, MA — Moderna Therapeutics a clinical stage biotechnology company, pioneering an experimental vaccine for the coronavirus, announced on Thursday that the Food and Drug Administration had cleared its application to proceed to a clinical trial involving about 600 people.

“The imminent Phase 2 study start is a crucial step forward,” Stéphane Bancel, Moderna’s chief executive, said in a statement.

The main goal of this set of tests is to find out if the vaccine is safe and if positive results from the first few dozen volunteers in the first phase can be replicated in a much larger group. If it is successful, later studies, known as Phase 3 trials, will determine exactly how well the vaccine works.

Moderna has manufactured and released more than 100 batches of vaccines and therapeutics from its Norwood site for human clinical trials and in late February shipped vials of its vaccine candidate to the National Institute of Allergy and Infectious Disease for further research.

Philanthropist Noubar Afeyan is the co-founder and chairman of Moderna Therapeutics. He is also co-founder of Aurora Prize for Awakening Humanity.

1 comment
Leave a Reply

Your email address will not be published. Required fields are marked *

Sign Up for Our Newsletters

Get notified of the latest updates from MassisPost.

You May Also Like

World Council of Churches to Observe the 100th Anniversary of the Armenian Genocide

The World Council of Churches (WCC) has addressed the issue of the…

Azerbaijani Ambassador to Serbia Arrested on Embezzlement Charges

BAKU — Azerbaijani Ambassador to Serbia Eldar Hasanov has been detained on…

Armenia’s Daily COVID-19 Cases Set Record High

YEREVAN — Armenia’s Ministry Health reports the number of positive COVID-19 cases…

Community Support Group for Residents Impacted by the Eaton and Palisades Fires

PASADENA – In the wake of the devastating Eaton and Palisades Fires,…